We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed
🧬 Transform therapies, reimagine lives. That’s exactly what Alumis does. 🌟 $ALMS is transforming the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies. 👏 In celebration of their listing on Nasdaq, Alumis joins us for the Opening Bell. Exciting! Stay tuned for more!
Congratulations team Alumis on this remarkable journey in precision medicines to tackle immune-mediated diseases.
Cheers to a bright future, Alumis! Excited about your upcoming advancements and strategic collaborations in immune-mediated disease treatments.
Congratulations team Alumis. Excited to be part of this journey!
Congratulations! I am very happy for Alumis and the whole team. Best wishes!
Impressive growth! Congrats team Alumis, especially my hard working pal Denise Winn, CPA (inactive)
So awesome to see another new biotech public company - congrats to Martin and the team!
Congratulations Jörn Drappa and many friends at Alumis
Awesome, congrats Alumis!
So thrilled to be your exchange partner!